WO1999025825A3 - EXTENDED cDNAs FOR SECRETED PROTEINS - Google Patents

EXTENDED cDNAs FOR SECRETED PROTEINS Download PDF

Info

Publication number
WO1999025825A3
WO1999025825A3 PCT/IB1998/001862 IB9801862W WO9925825A3 WO 1999025825 A3 WO1999025825 A3 WO 1999025825A3 IB 9801862 W IB9801862 W IB 9801862W WO 9925825 A3 WO9925825 A3 WO 9925825A3
Authority
WO
WIPO (PCT)
Prior art keywords
extended cdnas
secreted proteins
extended
cdnas
forensic
Prior art date
Application number
PCT/IB1998/001862
Other languages
French (fr)
Other versions
WO1999025825A2 (en
Inventor
Lydie Bougueleret
Aymeric Duclert
Milne Edwards Jean-Bapti Dumas
Original Assignee
Genset Sa
Lydie Bougueleret
Aymeric Duclert
Dumas Milne Edwards Jean Bapti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa, Lydie Bougueleret, Aymeric Duclert, Dumas Milne Edwards Jean Bapti filed Critical Genset Sa
Priority to CA002302644A priority Critical patent/CA2302644A1/en
Priority to EP98952974A priority patent/EP1029045A2/en
Priority to JP2000521191A priority patent/JP2001523453A/en
Priority to AU10491/99A priority patent/AU753099B2/en
Publication of WO1999025825A2 publication Critical patent/WO1999025825A2/en
Publication of WO1999025825A3 publication Critical patent/WO1999025825A3/en
Priority to AU2002301051A priority patent/AU2002301051B9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The sequences of extended cDNAs encoding secreted proteins are disclosed. The extended cDNAs can be used to express secreted proteins or portions thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The extended cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The extended cDNAs may also be used to design expression vectors and secretion vectors.
PCT/IB1998/001862 1997-08-01 1998-11-13 EXTENDED cDNAs FOR SECRETED PROTEINS WO1999025825A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002302644A CA2302644A1 (en) 1997-11-13 1998-11-13 Extended cdnas for secreted proteins
EP98952974A EP1029045A2 (en) 1997-11-13 1998-11-13 EXTENDED cDNAs FOR SECRETED PROTEINS
JP2000521191A JP2001523453A (en) 1997-11-13 1998-11-13 Extended cDNA of secreted protein
AU10491/99A AU753099B2 (en) 1997-08-01 1998-11-13 Extended cDNAs for secreted proteins
AU2002301051A AU2002301051B9 (en) 1997-08-01 2002-09-09 Extended cDNAs for secreted proteins

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US6667797P 1997-11-13 1997-11-13
US60/066,677 1997-11-13
US6995797P 1997-12-17 1997-12-17
US60/069,957 1997-12-17
US7412198P 1998-02-09 1998-02-09
US8156398P 1998-04-13 1998-04-13
US9611698P 1998-08-10 1998-08-10
US9927398P 1998-09-04 1998-09-04
US60/096,116 1998-09-04
US60/099,273 1998-09-04
US60/081,563 1998-09-04
US60/074,121 1998-09-04

Publications (2)

Publication Number Publication Date
WO1999025825A2 WO1999025825A2 (en) 1999-05-27
WO1999025825A3 true WO1999025825A3 (en) 1999-07-29

Family

ID=27556962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/001862 WO1999025825A2 (en) 1997-08-01 1998-11-13 EXTENDED cDNAs FOR SECRETED PROTEINS

Country Status (5)

Country Link
US (1) US20060223142A1 (en)
EP (1) EP1029045A2 (en)
JP (1) JP2001523453A (en)
CA (1) CA2302644A1 (en)
WO (1) WO1999025825A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
CA2281952C (en) 1997-02-25 2011-07-19 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001066740A2 (en) * 2000-03-03 2001-09-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6573068B1 (en) 1997-11-13 2003-06-03 Genset, S. A. Claudin-50 protein
DE19850015A1 (en) * 1998-10-30 2000-05-04 Max Delbrueck Centrum Proteins of the stomatin family and their use as target proteins for ore therapy
JP2002541804A (en) * 1999-04-09 2002-12-10 カイロン コーポレイション Secreted human protein
CN1244584A (en) * 1999-05-14 2000-02-16 北京医科大学 Chemotarix factor with immunocyte chemotaxis and hemopoinesis stimulating activity
EP1208202A2 (en) * 1999-09-01 2002-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001031004A1 (en) * 1999-10-27 2001-05-03 Takeda Chemical Industries, Ltd. Novel protein and use thereof
US20050095587A1 (en) * 2000-02-24 2005-05-05 Panzer Scott R. Molecules for disease detection and treatment
WO2001062927A2 (en) * 2000-02-24 2001-08-30 Incyte Genomics Inc Polypeptides and corresponding polynucleotides for diagnostics and therapeutics
CA2418496A1 (en) * 2000-02-24 2001-08-30 Incyte Genomics, Inc. Secretory polypeptides and corresponding polynucleotides
EP1311674A2 (en) * 2000-08-24 2003-05-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1364015A2 (en) * 2000-09-05 2003-11-26 Incyte Genomics, Inc. Molecules for diagnostics and therapeutics
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
EP1573024A4 (en) 2001-04-10 2007-08-29 Agensys Inc Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
WO2003027138A1 (en) 2001-09-25 2003-04-03 Japan As Represented By President Of National Cancer Center Search for cancer marker by novel screening method
US20070172843A1 (en) * 2005-09-12 2007-07-26 Conrad Susan E MEK interacting protein 1 as diagnostic and therapeutic target for breast cancer treatment and prevention
US8470323B2 (en) * 2007-01-09 2013-06-25 The Trustees Of The University Of Pennsylvania Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625572A1 (en) * 1992-09-25 1994-11-23 The Kanagawa Academy Of Science And Technology Foundation PROCESS FOR SYNTHESIZING COMPLETE-LENGTH cDNA, PROCESS FOR PRODUCING INTERMEDIATE THEREFOR, AND PROCESS FOR PRODUCING RECOMBINANT VECTOR CONTAINING COMPLETE-LENGTH cDNA
WO1996034981A2 (en) * 1995-05-02 1996-11-07 Genset Sa METHOD FOR THE SPECIFIC COUPLING OF THE CAP OF THE EXTREMITY 5' OF A FRAGMENT mRNA AND PREPARATION OF mRNA AND COMPLETE cDNA
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby
WO1998045436A2 (en) * 1997-04-10 1998-10-15 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
WO1999006548A2 (en) * 1997-08-01 1999-02-11 Genset 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625572A1 (en) * 1992-09-25 1994-11-23 The Kanagawa Academy Of Science And Technology Foundation PROCESS FOR SYNTHESIZING COMPLETE-LENGTH cDNA, PROCESS FOR PRODUCING INTERMEDIATE THEREFOR, AND PROCESS FOR PRODUCING RECOMBINANT VECTOR CONTAINING COMPLETE-LENGTH cDNA
WO1996034981A2 (en) * 1995-05-02 1996-11-07 Genset Sa METHOD FOR THE SPECIFIC COUPLING OF THE CAP OF THE EXTREMITY 5' OF A FRAGMENT mRNA AND PREPARATION OF mRNA AND COMPLETE cDNA
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby
WO1998045436A2 (en) * 1997-04-10 1998-10-15 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
WO1999006548A2 (en) * 1997-08-01 1999-02-11 Genset 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CARNINCI P. ET AL.: "High-efficiency full-length cDNA cloning by biotinylated CAP trapper", GENOMICS, vol. 37, no. 3, 1 November 1996 (1996-11-01), pages 327 - 336, XP002081729 *
Database EMBL, Entry HS409287 Accession number N57409 29 February 1996 100% identity with Seq.ID:134 nt.581-1041 reverse orientation *
Database EMBL, Entry HSA57573 Accession number AA057573 19 September 1996 98% identity with Seq.ID:134 nt.102-746 *
Database EMBL, Entry HST03538 Accession number T03538 24 August 1993 97% identity with Seq.ID:134 nt.48-499 *
HEIJNE VON G.: "A new method for predicting signal sequence cleavage sites", NUCLEIC ACIDS RESEARCH, vol. 14, no. 11, 1986, pages 4683 - 4690, XP002053954 *
KATO S. ET AL.: "Construction of a human full-length cDNA bank", GENE, vol. 150, 1994, pages 243 - 250, XP002081364 *
LOCKHART D.J. ET AL.: "Expression monitoring by hybridization to high-density oligonucleotide arrays", BIO/TECHNOLOGY, no. 14, 14 December 1996 (1996-12-14), pages 1675 - 1680, XP002074420 *
TASHIRO K. ET AL.: "Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins", SCIENCE, vol. 261, 30 July 1993 (1993-07-30), pages 600 - 603, XP000673204 *
YOKOYAMA-KOBAYASHI M. ET AL.: "A signal sequence detection system using secreted protease activity as an indicator", GENE, vol. 163, 1995, pages 193 - 196, XP002053953 *

Also Published As

Publication number Publication date
CA2302644A1 (en) 1999-05-27
US20060223142A1 (en) 2006-10-05
EP1029045A2 (en) 2000-08-23
JP2001523453A (en) 2001-11-27
WO1999025825A2 (en) 1999-05-27

Similar Documents

Publication Publication Date Title
WO1999031236A3 (en) EXTENDED cDNAs FOR SECRETED PROTEINS
WO1999025825A3 (en) EXTENDED cDNAs FOR SECRETED PROTEINS
WO1999040189A3 (en) Cdnas encoding secreted proteins
WO2001000806A3 (en) Dna's encoding proteins with signal peptides
WO2000037491A3 (en) Dnas encoding proteins with signal sequences
WO2002014358A3 (en) Novel secreted proteins and their uses
WO1999006548A3 (en) 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS
WO1999006550A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE
WO1999006552A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN BRAIN
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
WO1999006554A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
WO1999006549B1 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN TESTIS AND OTHER TISSUES
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
WO1999053051A3 (en) 5' ests and encoded human proteins
WO1998031800A3 (en) Human proteins
WO1998021343A8 (en) Genes encoding telomerase proteins
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
WO1999006551A3 (en) 5' ESTs FOR SECRETED PROTEINS IDENTIFIED FROM BRAIN TISSUES
WO1999006439A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN ENDODERM
EP1375514A3 (en) 5'ESTs for secreted proteins expressed in various tissues
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
WO2000052136A3 (en) Human glycosylation enzymes
WO2002036627A3 (en) Interferons, uses and compositions related thereto

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2302644

Country of ref document: CA

Ref country code: CA

Ref document number: 2302644

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998952974

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10491/99

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1998952974

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 10491/99

Country of ref document: AU